Opdivo, Twitter, 7/13/2019 6:01:43 AM, 202976


FAQ | Problem?

Opdivo_2019-07-12_15-02-19.xlsx
Opdivo_2019-07-12_15-02-19.xlsx
From:
NodeXLExcelAutomator
Uploaded on:
July 13, 2019
Short Description:
Opdivo via NodeXL http://bit.ly/32rFrlm
@satoruo
@bmsnews
@lucidhealthcon
@adamfeuerstein
@infocancerfoie
@gambiste1
@jacobplieth
@augustonyc
@mvas52
@bclc_group

Top hashtags:
#opdivo
#nivolumab
#zoladex
#rituximab
#avastin
#nexavar
#caracas
#sutent
#sorafenib

Description:
Description
The graph represents a network of 1,138 Twitter users whose tweets in the requested range contained "Opdivo", or who were replied to or mentioned in those tweets. The network was obtained from the NodeXL Graph Server on Friday, 12 July 2019 at 22:02 UTC.

The requested start date was Thursday, 11 July 2019 at 00:01 UTC and the maximum number of tweets (going backward in time) was 5,000.

The tweets in the network were tweeted over the 70-day, 15-hour, 7-minute period from Wednesday, 01 May 2019 at 00:44 UTC to Wednesday, 10 July 2019 at 15:51 UTC.

Additional tweets that were mentioned in this data set were also collected from prior time periods. These tweets may expand the complete time period of the data.

There is an edge for each "replies-to" relationship in a tweet, an edge for each "mentions" relationship in a tweet, and a self-loop edge for each tweet that is not a "replies-to" or "mentions".

The graph is directed.

The graph's vertices were grouped by cluster using the Clauset-Newman-Moore cluster algorithm.

The graph was laid out using the Harel-Koren Fast Multiscale layout algorithm.


Author Description


Overall Graph Metrics
Vertices : 1138
Unique Edges : 1133
Edges With Duplicates : 759
Total Edges : 1892
Number of Edge Types : 3
Mentions : 1139
Tweet : 599
Replies to : 154
Self-Loops : 599
Reciprocated Vertex Pair Ratio : 0.0102354145342886
Reciprocated Edge Ratio : 0.0202634245187437
Connected Components : 325
Single-Vertex Connected Components : 236
Maximum Vertices in a Connected Component : 203
Maximum Edges in a Connected Component : 426
Maximum Geodesic Distance (Diameter) : 13
Average Geodesic Distance : 3.754614
Graph Density : 0.000762806571729322
Modularity : 0.568142
NodeXL Version : 1.0.1.413

Top Influencers: Top 10 Vertices, Ranked by Betweenness Centrality
Top URLs
Top URLs in Tweet in Entire Graph:
[28] https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-459-study-evaluating-opdivo-nivol
[13] https://www.fiercepharma.com/pharma/merck-s-keytruda-passing-opdivo-bags-double-head-and-neck-cancer-ok
[12] https://www.reuters.com/article/us-bristol-myers-cancer/bristol-myers-opdivo-fails-late-stage-brain-cancer-trial-idUSKCN1SF1B8?feedType=RSS&feedName=healthNews
[10] http://brazilsfecompany.blogspot.com.br/2018/04/2018-Top-20-Medicamentos-Mais-Vendidos-no-Mundo.html
[10] https://twitter.com/BrazilSFE
[10] http://benzaiten.dyndns.org/roller/ugya/entry/honjo-tasuku-opdivo
[9] https://medcitynews.com/2019/05/bmss-immunotherapy-drug-opdivo-fails-in-phase-iii-brain-cancer-study/
[8] https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-459-study-evaluating-opdivo-nivol?linkId=69441570
[7] https://endpts.com/bristol-myers-star-opdivo-fails-survival-test-in-a-matchup-with-nexavar-aimed-at-shaking-up-the-big-hcc-market/
[7] http://cn.nikkei.com/politicsaeconomy/politicsasociety/35516-2019-05-10-10-46-48.html

Top URLs in Tweet in G1:
[12] https://www.reuters.com/article/us-bristol-myers-cancer/bristol-myers-opdivo-fails-late-stage-brain-cancer-trial-idUSKCN1SF1B8?feedType=RSS&feedName=healthNews
[10] http://brazilsfecompany.blogspot.com.br/2018/04/2018-Top-20-Medicamentos-Mais-Vendidos-no-Mundo.html
[10] https://twitter.com/BrazilSFE
[6] https://www.fiercepharma.com/pharma/merck-s-keytruda-passing-opdivo-bags-double-head-and-neck-cancer-ok
[5] https://www.reuters.com/article/us-bristol-myers-cancer/bristol-myers-opdivo-fails-late-stage-brain-cancer-trial-idUSKCN1SF1B8?feedType=RSS&feedName=healthNews&utm_source=dlvr.it&utm_medium=twitter
[5] https://medcitynews.com/2019/05/bmss-immunotherapy-drug-opdivo-fails-in-phase-iii-brain-cancer-study/
[5] https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-459-study-evaluating-opdivo-nivol
[4] https://www.reuters.com/article/us-bristol-myers-cancer/bristol-myers-opdivo-fails-late-stage-brain-cancer-trial-idUSKCN1SF1B8
[4] https://www.buzzfeed.com/jp/satoruosuka/cancer-opdivo?utm_source=dynamic&utm_campaign=bfsharetwitter
[4] https://lungcancersymptomsx.com/a-hope-for-mesothelioma-patients-with-new-lung-cancer-drug-opdivo.html

Top URLs in Tweet in G2:
[1] https://www.buzzfeed.com/jp/satoruosuka/cancer-opdivo?utm_source=dynamic&utm_campaign=bfsharetwitter

Top URLs in Tweet in G3:
[2] https://www.youtube.com/watch?v=WDDxSO_7DxU

[2] https://seekingalpha.com/news/3473157
[2] https://endpts.com/bristol-myers-star-opdivo-fails-survival-test-in-a-matchup-with-nexavar-aimed-at-shaking-up-the-big-hcc-market/
[2] https://twitter.com/bio_clouseau/status/1143111436241162241
[2] https://www.fiercebiotech.com/biotech/complete-response-rate-nektar-melanoma-trial-hits-34
[1] http://dlvr.it/R6lvY5
[1] http://dlvr.it/R8347p
[1] http://ir.beigene.com/news-releases/news-release-details/beigene-regains-full-global-rights-its-investigational-anti-pd-1
[1] http://clincancerres.aacrjournals.org/content/early/2019/06/25/1078-0432.CCR-18-3944
[1] http://ir.exelixis.com/news-releases/news-release-details/exelixis-initiating-phase-3-pivotal-trial-cosmic-313

Top URLs in Tweet in G6:
[15] https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-459-study-evaluating-opdivo-nivol
[4] https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-459-study-evaluating-opdivo-nivol?linkId=69441570
[3] https://bit.ly/2x70MSX
[1] https://twitter.com/InfoCancerFoie/status/1143217317888823296
[1] https://clinicaltrials.gov/ct2/show/NCT02576509?term=nivolumab+checkmate&cond=Hepatocellular+Carcinoma&rank=3

Top URLs in Tweet in G7:
[4] https://news.bms.com/press-release/asco19/bristol-myers-squibb-announces-first-presentation-results-opdivo-nivolumab-plus?linkId=68472488
[3] https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-459-study-evaluating-opdivo-nivol?linkId=69441570
[3] https://pharmaphorum.com/views-and-analysis/rd-roundup-novartis-crispr-opdivo/
[3] https://finance.yahoo.com/news/bristol-myers-bmy-presents-multiple-130301742.html
[2] http://www.pharmatimes.com/news/bms_opdivo_disappoints_in_late-stage_trial_1292613
[2] https://pharmaphorum.com/news/bms-has-another-opdivo-setback-after-liver-cancer-trial-failure/?utm_source=pharmaphorum+Daily+Newsletter&utm_campaign=e64cb98ac2-EMAIL_CAMPAIGN_2019_06_25_11_55&utm_medium=email&utm_term=0_a54496134b-e64cb98ac2-438901029
[2] http://www.pharmatimes.com/news/imfinzi,_opdivo_among_latest_smc_decisions_1290505
[2] https://medcitynews.com/2019/06/nektars-bempeg-shows-encouraging-phase-ii-data-in-first-line-melanoma-with-bms-opdivo/
[1] https://www.businesswire.com/news/home/20181209005013/en/Bristol-Myers-Squibb-Vedanta-Biosciences-Announce-New-Clinical
[1] https://pharmaphorum.com/news/bms-opdivo-fails-late-stage-brain-cancer-test/

Top URLs in Tweet in G9:
[1] https://www.opdivo.jp/drug_info_files/drug_info/opdivo/info/21000218/OPD_oshirase_201905.pdf
[1] https://www.nikkei.com/article/DGXMZO44583610Z00C19A5CR8000/

Top URLs in Tweet in G10:
[2] https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-completes-enrollment-controlled-il-12-plus
[1] https://twitter.com/MVAS52/status/1128343252564881410
[1] https://www.curetoday.com/articles/presurgical-opdivo-may-benefit-patients-with-glioblastoma
[1] https://twitter.com/bmsnews/status/1135502392873619456
[1] https://www.globenewswire.com/news-release/2019/06/26/1874467/0/en/Ziopharm-Oncology-Completes-Enrollment-of-Controlled-IL-12-plus-Opdivo-nivolumab-Phase-1-Combination-Trial-in-Brain-Cancer.html
[1] https://seekingalpha.com/news/3461627

Top Domains
Top Domains in Tweet in Entire Graph:
[44] bms.com
[43] fiercepharma.com
[36] twitter.com
[26] reuters.com
[24] dlvr.it
[22] medcitynews.com
[17] co.jp
[12] blogspot.com
[11] seekingalpha.com
[11] com.br

Top Domains in Tweet in G1:
[24] reuters.com
[19] fiercepharma.com
[16] twitter.com
[15] medcitynews.com
[12] dlvr.it
[11] com.br
[10] co.jp
[9] blogspot.com
[9] jiho.jp
[7] einnews.com

Top Domains in Tweet in G2:
[1] buzzfeed.com

Top Domains in Tweet in G3:
[7] twitter.com
[4] dlvr.it
[3] bms.com
[3] endpts.com
[2] youtube.com
[2] seekingalpha.com
[2] businesswire.com
[2] fiercebiotech.com
[1] beigene.com
[1] aacrjournals.org

Top Domains in Tweet in G6:
[19] bms.com
[3] bit.ly
[1] twitter.com
[1] clinicaltrials.gov

Top Domains in Tweet in G7:
[8] bms.com
[8] pharmaphorum.com
[5] pharmatimes.com
[3] pharmaceutical-technology.com
[3] yahoo.com
[3] medcitynews.com
[2] pharmashots.com
[2] twitter.com
[1] businesswire.com
[1] drugdevelopment-technology.com

Top Domains in Tweet in G9:
[1] opdivo.jp
[1] nikkei.com

Top Domains in Tweet in G10:
[2] twitter.com
[2] ziopharm.com
[1] curetoday.com
[1] globenewswire.com
[1] seekingalpha.com

Top Hashtags
Top Hashtags in Tweet in Entire Graph:
[140] opdivo
[88] nivolumab
[47] zoladex
[46] rituximab
[46] avastin
[38] nexavar
[35] caracas
[26] sutent
[25] sorafenib
[24] capecitabina



Top Hashtags in Tweet in G1:
[39] opdivo
[12] januvia
[12] lantus
[12] prevnar13
[12] neulasta
[11] nivolumab
[10] janumet
[10] prevener
[10] peglasta
[10] neupogen

Top Hashtags in Tweet in G3:
[8] nivolumab
[6] asco19
[3] carcinome
[3] opdivo
[2] sorafenib
[1] dcvax
[1] chimiothérapie
[1] cetuximab
[1] cabozantinib
[1] ipilimumab

Top Hashtags in Tweet in G4:
[58] opdivo
[48] nivolumab
[47] zoladex
[46] rituximab
[37] nexavar
[35] caracas
[32] avastin
[24] capecitabina
[23] docetaxel
[22] xeloda

Top Hashtags in Tweet in G6:
[8] hcc
[5] hepatocellularcarcinoma
[5] livercancer
[5] treatment
[3] pressrelease
[2] nivolumab
[2] sorafenib
[1] media

Top Hashtags in Tweet in G7:
[8] melanoma
[7] hcc
[6] media
[5] asco19
[5] pharma
[4] pharmanews
[4] opdivo
[3] trial
[3] clinicaltrial
[2] cancer

Top Hashtags in Tweet in G10:
[1] asco19
[1] opdivo
[1] immunooncology
[1] glioblastoma

Top Words
Top Words in Tweet in Entire Graph:
[650] Words in Sentiment List#1: Positive
[788] Words in Sentiment List#2: Negative
[2] Words in Sentiment List#3: Angry/Violent
[27378] Non-categorized Words
[28816] Total Words
[902] opdivo
[289] cancer
[266] nivolumab
[257] bristol
[193] trial

Top Words in Tweet in G1:
[326] opdivo
[154] cancer
[142] bristol
[93] fails
[86] trial
[81] myers
[80] brain
[77] phase
[76] nivolumab
[73] study

Top Words in Tweet in G2:
[187] satoruo
[187] がんと免疫については
[187] 以前にバズフィードに解説記事を書いています
[187] 免疫はたしかにがん治療に重要なのですが
[187] それを一般生活にある食品
[187] 食事療法などで
[187] 大きく変えて
[187] がん細胞を殺せるような変化を起こすことは困難であることがわかっています
[187] 記事をご参考に
[66] ã

Top Words in Tweet in G3:
[102] opdivo
[75] bmy
[37] line
[28] fails
[22] keytruda
[22] cm
[21] study
[20] cancer
[19] adamfeuerstein
[18] phase

Top Words in Tweet in G4:
[58] #opdivo
[48] #nivolumab
[47] #zoladex
[46] #rituximab
[42] serviciopublive
[39] medcancervzla
[37] #nexavar
[36] ayudasosvzla
[35] #caracas
[34] donamed_ve

Top Words in Tweet in G5:
[62] bir
[61] 2
[60] barisyarkadas
[60] kutusu
[60] 28
[60] bin
[60] tl'den
[60] satılan
[60] ve
[60] ay

Top Words in Tweet in G6:
[51] sorafenib
[50] nivolumab
[35] survival
[33] improve
[26] trial
[25] results
[25] checkmate
[25] 459
[24] overall
[20] show

Top Words in Tweet in G7:
[42] opdivo
[30] bmsnews
[11] phase
[9] data
[9] patients
[9] study
[8] nivolumab
[8] #melanoma
[7] #hcc
[7] cancer

Top Words in Tweet in G8:
[3] vprasadmdmph
[3] opdivo
[2] drugs
[2] before
[2] pd
[2] new
[2] bristol

Top Words in Tweet in G9:
[18] オプジーボの副作用報道
[18] 従来も記載
[18] 認識されていた下垂体機能障害を
[18] 重大な副作用
[18] に格上げしたものであり
[18] その頻度の低さ
[18] 適切に検査で発見し処置可能であることを考えれば
[18] その効果を天秤に計ると騒ぎすぎだと感じます
[17] biotechmania

Top Words in Tweet in G10:
[40] opdivo
[27] data
[24] trial
[21] combo
[19] ziop
[18] 1
[16] 12
[14] il
[13] controlled
[13] phase

Top Word Pairs
Top Word Pairs in Tweet in Entire Graph:
[187] がんと免疫については,以前にバズフィードに解説記事を書いています
[187] 以前にバズフィードに解説記事を書いています,免疫はたしかにがん治療に重要なのですが
[187] 免疫はたしかにがん治療に重要なのですが,それを一般生活にある食品
[187] それを一般生活にある食品,食事療法などで
[187] 食事療法などで,大きく変えて
[187] 大きく変えて,がん細胞を殺せるような変化を起こすことは困難であることがわかっています
[187] がん細胞を殺せるような変化を起こすことは困難であることがわかっています,記事をご参考に
[186] satoruo,がんと免疫については
[170] bristol,myers
[137] opdivo,fails

Top Word Pairs in Tweet in G1:
[84] opdivo,fails
[81] bristol,myers
[74] brain,cancer
[59] opdivo,nivolumab
[58] late,stage
[54] cancer,trial
[53] stage,brain
[51] bristol,myers'
[50] myers',opdivo
[47] fails,late

Top Word Pairs in Tweet in G2:
[187] がんと免疫については,以前にバズフィードに解説記事を書いています
[187] 以前にバズフィードに解説記事を書いています,免疫はたしかにがん治療に重要なのですが
[187] 免疫はたしかにがん治療に重要なのですが,それを一般生活にある食品
[187] それを一般生活にある食品,食事療法などで
[187] 食事療法などで,大きく変えて
[187] 大きく変えて,がん細胞を殺せるような変化を起こすことは困難であることがわかっています
[187] がん細胞を殺せるような変化を起こすことは困難であることがわかっています,記事をご参考に
[186] satoruo,がんと免疫については
[38] ã,ã
[6] ã,œã

Top Word Pairs in Tweet in G3:
[24] bmy,opdivo
[18] opdivo,fails
[16] 1st,line
[14] fails,1st
[14] glioblastoma,tough
[14] tough,cancer
[14] cancer,crack
[14] crack,today
[14] today,s
[14] s,failure

Top Word Pairs in Tweet in G4:
[33] #opdivo,#nivolumab
[23] #rituximab,#capecitabina
[22] #caracas,#rituximab
[22] #capecitabina,#xeloda
[22] #xeloda,#taxol
[22] #taxol,#nexavar
[22] #nexavar,#zoldonat
[22] #zoldonat,#zoladex
[22] #zoladex,#opdivo
[22] #nivolumab,#docetaxel

Top Word Pairs in Tweet in G5:
[60] 2,kutusu
[60] kutusu,28
[60] 28,bin
[60] bin,tl'den
[60] tl'den,satılan
[60] satılan,ve
[60] ve,ay
[60] ay,kullanılmak
[60] kullanılmak,zorunda
[60] zorunda,opdivo

Top Word Pairs in Tweet in G6:
[25] checkmate,459
[22] overall,survival
[20] results,checkmate
[20] 459,trial
[20] trial,show
[20] show,nivolumab
[20] nivolumab,improve
[20] improve,overall
[20] survival,compared
[20] compared,sorafenib

Top Word Pairs in Tweet in G7:
[7] bristol,myers
[5] myers,squibb
[4] bmsnews,#media
[4] phase,3
[4] immuno,oncology
[4] bms,opdivo
[4] opdivo,fails
[4] bmsnews,announced
[4] opdivo,nivolumab
[4] nivolumab,opdivo

Top Word Pairs in Tweet in G9:
[18] オプジーボの副作用報道,従来も記載
[18] 従来も記載,認識されていた下垂体機能障害を
[18] 認識されていた下垂体機能障害を,重大な副作用
[18] 重大な副作用,に格上げしたものであり
[18] に格上げしたものであり,その頻度の低さ
[18] その頻度の低さ,適切に検査で発見し処置可能であることを考えれば
[18] 適切に検査で発見し処置可能であることを考えれば,その効果を天秤に計ると騒ぎすぎだと感じます
[17] biotechmania,オプジーボの副作用報道

Top Word Pairs in Tweet in G10:
[14] il,12
[13] controlled,il
[11] opdivo,nivolumab
[11] combination,trial
[10] 12,plus
[10] plus,opdivo
[10] phase,1
[10] 1,combination
[7] brain,cancer
[7] combo,data

Top Replied-To
Top Replied-To in Entire Graph:
@thenci
@fundacionbadan
@bmsnews
@julioespinoza4
@buscandomedicin
@bradloncar
@medcancervzla
@ca601ff0a58d454
@veteranshealth
@ncicancertrials

Top Replied-To in G3:
@adamfeuerstein
@bradloncar
@bursatilbiotech
@rogerb06385286
@drugchannels
@matthewherper
@fiercebiotech
@stockmatusow
@zbiotech

Top Replied-To in G4:
@fundacionbadan
@buscandomedicin
@medcancervzla
@julioespinoza4
@freddyflash1
@serviciopublive
@ca601ff0a58d454
@maydavila1

Top Replied-To in G5:
@barisyarkadas

Top Replied-To in G7:
@bmsnews
@nektar
@curemelanoma

Top Replied-To in G8:
@rskemp01
@mikejohansenmd
@akapczynski

Top Replied-To in G10:
@bradloncar
@dodawuk
@mvas52

Top Mentioned
Top Mentioned in Entire Graph:
@satoruo
@barisyarkadas
@serviciopublive
@medcancervzla
@ayudasosvzla
@donamed_ve
@bmsnews
@sebuscasedona
@buscandomedicin
@sosmedicina

Top Mentioned in G1:
@clinicalphase
@cmencke
@judsontelemed
@ray_noble1
@womens_womens
@nailethv
@lmmarknaden
@larvol
@lungcancer_bio

Top Mentioned in G2:
@satoruo

Top Mentioned in G3:
@adamfeuerstein
@johncendpts
@bradloncar
@jacobplieth
@biostocks
@endpts
@dewdiligence
@matthewherper
@jimcramer
@bio_clouseau

Top Mentioned in G4:
@serviciopublive
@medcancervzla
@ayudasosvzla
@donamed_ve
@sebuscasedona
@buscandomedicin
@sosmedicina
@publserv
@esedesalud
@medicinasve

Top Mentioned in G5:
@barisyarkadas

Top Mentioned in G6:
@bclc_group
@augustonyc
@aeehliver
@infocancerfoie
@bmsnews
@dufour_jf
@jturnesv
@adiazgonzalezmd

Top Mentioned in G7:
@bmsnews
@biotechvisigoth
@xbranebiopharma
@medcitynews
@pharmatimes
@curemelanoma
@nektar
@rightrelevance
@vedantabio
@novartis

Top Mentioned in G8:
@vprasadmdmph
@venkmurthy
@oncology_bg
@drjohnm
@cmichaelgibson
@onco_cardiology
@drmarthagulati
@purviparwani
@roguerad
@anish_koka

Top Mentioned in G9:
@biotechmania

Top Mentioned in G10:
@biotech2050
@ziopharm
@mvas52
@dodawuk
@aiims1742
@brighamwomens
@brighamresearch

Top Tweeters
Top Tweeters in Entire Graph:
@myalliesnews
@follementbijoux
@allstocknews
@rocketnews1
@politicalhedge
@razzletazzlemag
@tradnews_
@marketcurrents
@gogiuk
@newsfromspi

Top Tweeters in G1:
@myalliesnews
@follementbijoux
@allstocknews
@rocketnews1
@politicalhedge
@razzletazzlemag
@marketcurrents
@gogiuk
@newsfromspi
@crweworld

Top Tweeters in G2:
@hayohater
@suigadou
@kumikokatase
@kinginsunago
@kgn_works
@socio34050
@mifasorahula
@aim54_phoenix
@maetaru2
@alcedo_kawasemi

Top Tweeters in G3:
@bioportfolio
@cancer_bio
@gambiste1
@jimcramer
@blossomvinson
@portefeuillefun
@matthewherper
@pnani456
@stockmatusow
@adamfeuerstein

Top Tweeters in G4:
@serviciopublive
@tamaracoromoto
@donamed_ve
@chuotorrealba
@fundatiacruz
@anonmundial
@sebuscasedona
@fundacionbadan
@aclave
@ayudasosvzla

Top Tweeters in G5:
@barisyarkadas
@no_rumuz
@ezgisutoprak
@sebahatturkmen
@nathan61641442
@kkbirocuk1
@fkoruyucu1
@zehrabozca
@svmaktryldz
@meralyilmazlar

Top Tweeters in G6:
@drjhk
@fpazgomez
@tamarnegie
@hakosemi
@carmenvcello
@sepdigestiva
@rplanasv
@jturnesv
@drjaviercrespo
@birminghamliver

Top Tweeters in G7:
@hernangraffe
@pharmaphorum
@ci4cc
@chocolatierep
@medcitynews
@mimigirlsmom
@lizchristensen2
@pharmatimes
@mo7d3del
@thepharmaletter

Top Tweeters in G8:
@drmarthagulati
@cmichaelgibson
@roguerad
@vprasadmdmph
@venkmurthy
@onco_cardiology
@cdcgov
@oncology_bg
@anish_koka
@purviparwani

Top Tweeters in G9:
@rijin_nakamura
@dominique_domon
@chokosh0120
@kantaiheiyo1
@lapin214_gn
@chemordie
@mori_nobu
@steroidinlondon
@data_tinkerman
@d10868999

Top Tweeters in G10:
@biotech2050
@heyjt55
@aiims1742
@big4biobos
@ayjayg_15
@brighamwomens
@brighamresearch
@mvas52
@aesculapius1898
@mcareynj


We use necessary cookies to make our site work. We’d like to set additional cookies to understand site usage, make site improvements and to remember your settings. We also use cookies set by other sites to help deliver content from their services.